Evaluation of Melatonin and Metformin Loaded Nanoparticles in the Treatment of Periodontal Intra-bony Defects
Launched by AMIRA RAGAB · Jun 13, 2023
Trial Information
Current as of May 06, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with at least one intra-bony defect diagnosed clinically and radiographically
- Exclusion Criteria:
- • Patients with systemic diseases.
- • Pregnant and lactating females.
- • Smokers and tobacco chewers.
- • History of antibiotic and periodontal therapy in the last 3 months.
- • Patients not compliant with oral hygiene procedures.
- • Patients with a known or suspected allergy to the melatonin or metformin.
- • Individuals on systemic drug affecting metabolic bone diseases and medically compromised patients.
About Amira Ragab
Amira Ragab is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong commitment to rigorous scientific standards and ethical practices, Amira Ragab collaborates with leading healthcare professionals and research institutions to design, conduct, and manage clinical trials across various therapeutic areas. The organization emphasizes transparency, participant safety, and the integration of cutting-edge technologies, aiming to contribute significantly to the development of effective treatments and enhance the overall healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mansoura, Dakhlia, Egypt
Patients applied
Trial Officials
Amira R AL-Agooz
Principal Investigator
Mansoura University, Faculty of Dentistry
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported